Second take on short-supply drug markups exonerates distributors

Rep. Elijah Cummings may have overstated alleged "gray market" price-gouging for drugs in short supply and done a public disservice to small distributors, according to Superior Medical Supply, one of his probe targets. In early October, Cummings cited data from a report published by group purchaser Premier health alliance showing that short-supply drug markups average 650% and have reached 4,500%. Pharmaceutical Commerce reported last week that Premier acknowledged its data showed a markup range of 29% to 729%. Plus, the comparison ignores the "market reality" that prices negotiated by group purchasers are generally 40% to 50% lower than the small distributor cost, says a statement from the National Coalition of Pharmaceutical Distributors. Letter | Story | NCPD release

Suggested Articles

Dr. Reddy’s says it has been told the FDA will not take regulatory action at its sterile formulations plant in Duvvada, Visakhapatnam.

The end is near for a GlaxoSmithKline OTC plant in Pennsylvania and its 260 employees. In fact, it has a date. 

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.